Alkermes plc
Mid Cap · Healthcare · Drug Manufacturers - Specialty & Generic
$49.50−$0.35 (-0.70%)
Alkermes plc
Mid Cap · Healthcare · Drug Manufacturers - Specialty & Generic
$49.50−$0.35 (-0.70%)
Stock analysis
Get the AI take on ALKS
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$25.17
High$55.67
Today $49.50
RSI (14)
34.3Neutral
03070100
Overall score
37/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$38
Current price
$49.5
Median target
$58
Highest
$72
LowHigh
Operating Record
Revenue
What's working
- Current ratio: What's on hand comfortably covers the bills due over the next year.
What to watch
- Debt exceeds cash by $916.0M, increasing balance-sheet pressure, a warning sign.
- Forward P/E: The price already assumes strong earnings growth that still has to show up.
What the market charges
Forward P/E
Needs attention · 433% above avg
31.19x
Price / sales
Reasonable · Priced reasonably against its revenue
4.94x
Price / FCF
Rich · Priced far above what its cash flow currently supports
37.13x
EV / EBITDA
Rich · Operating earnings don't yet support this price
32.10x
How efficiently it compounds
ROIC
Weak · Struggling to earn much on the capital it uses
5.5%
ROE
Middle ground · Mixed
3.9%
Debt / equity
Middle ground · Mixed
0.87x
Current ratio
Strong · Comfortable room to cover bills due within a year
2.30x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $8.23B | 127.4 | +10.8% | 37 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |